Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma
The long-term outcomes of interferon-alpha (IFN-α) therapy in hepatitis B e antigen (HBeAg) seropositive patients remain controversial. This study was conducted to address this issue. The long-term outcomes were compared in 233 IFN-treated patients and 233 well-matched untreated controls. The cumula...
Saved in:
| Published in | Journal of hepatology Vol. 46; no. 1; pp. 45 - 52 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford
Elsevier B.V
01.01.2007
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0168-8278 1600-0641 |
| DOI | 10.1016/j.jhep.2006.08.021 |
Cover
| Abstract | The long-term outcomes of interferon-alpha (IFN-α) therapy in hepatitis B e antigen (HBeAg) seropositive patients remain controversial. This study was conducted to address this issue.
The long-term outcomes were compared in 233 IFN-treated patients and 233 well-matched untreated controls.
The cumulative incidence at the end of 15 years of follow-up (median 6.8 years, range 1.1–16.5 years) in the IFN-treated patients and controls was: HBeAg seroconversion 74.6% vs. 51.7% (
P
=
0.031); hepatitis B surface antigen (HBsAg) seroclearance 3% vs. 0.4% (
P
=
0.03); cirrhosis 17.8% vs. 33.7% (
P
=
0.041); and hepatocellular carcinoma (HCC) 2.7% vs. 12.5% (
P
=
0.011). Significant reduction of HCC was only observed in patients with pre-existing cirrhosis (
P
<
0.01). Compared with untreated controls with persistent HBeAg, HBeAg seroconverters in untreated and IFN-treated group showed significantly lower incidence of cirrhosis and HCC (
P
=
0.003–0.031), while non-seroconverters of IFN-treated group had marginally significant lower incidence of cirrhosis (
P
=
0.065). Multivariate analysis showed that IFN therapy, HBeAg seroconversion and genotype B HBV infection are independent factors for better long-term outcomes.
IFN therapy reduces cirrhosis and HCC development. |
|---|---|
| AbstractList | The long-term outcomes of interferon-alpha (IFN-α) therapy in hepatitis B e antigen (HBeAg) seropositive patients remain controversial. This study was conducted to address this issue.
The long-term outcomes were compared in 233 IFN-treated patients and 233 well-matched untreated controls.
The cumulative incidence at the end of 15 years of follow-up (median 6.8 years, range 1.1–16.5 years) in the IFN-treated patients and controls was: HBeAg seroconversion 74.6% vs. 51.7% (
P
=
0.031); hepatitis B surface antigen (HBsAg) seroclearance 3% vs. 0.4% (
P
=
0.03); cirrhosis 17.8% vs. 33.7% (
P
=
0.041); and hepatocellular carcinoma (HCC) 2.7% vs. 12.5% (
P
=
0.011). Significant reduction of HCC was only observed in patients with pre-existing cirrhosis (
P
<
0.01). Compared with untreated controls with persistent HBeAg, HBeAg seroconverters in untreated and IFN-treated group showed significantly lower incidence of cirrhosis and HCC (
P
=
0.003–0.031), while non-seroconverters of IFN-treated group had marginally significant lower incidence of cirrhosis (
P
=
0.065). Multivariate analysis showed that IFN therapy, HBeAg seroconversion and genotype B HBV infection are independent factors for better long-term outcomes.
IFN therapy reduces cirrhosis and HCC development. The long-term outcomes of interferon-alpha (IFN-alpha) therapy in hepatitis B e antigen (HBeAg) seropositive patients remain controversial. This study was conducted to address this issue. The long-term outcomes were compared in 233 IFN-treated patients and 233 well-matched untreated controls. The cumulative incidence at the end of 15 years of follow-up (median 6.8 years, range 1.1-16.5 years) in the IFN-treated patients and controls was: HBeAg seroconversion 74.6% vs. 51.7% (P=0.031); hepatitis B surface antigen (HBsAg) seroclearance 3% vs. 0.4% (P=0.03); cirrhosis 17.8% vs. 33.7% (P=0.041); and hepatocellular carcinoma (HCC) 2.7% vs. 12.5% (P=0.011). Significant reduction of HCC was only observed in patients with pre-existing cirrhosis (P<0.01). Compared with untreated controls with persistent HBeAg, HBeAg seroconverters in untreated and IFN-treated group showed significantly lower incidence of cirrhosis and HCC (P=0.003-0.031), while non-seroconverters of IFN-treated group had marginally significant lower incidence of cirrhosis (P=0.065). Multivariate analysis showed that IFN therapy, HBeAg seroconversion and genotype B HBV infection are independent factors for better long-term outcomes. IFN therapy reduces cirrhosis and HCC development. The long-term outcomes of interferon-alpha (IFN-alpha) therapy in hepatitis B e antigen (HBeAg) seropositive patients remain controversial. This study was conducted to address this issue.BACKGROUND/AIMSThe long-term outcomes of interferon-alpha (IFN-alpha) therapy in hepatitis B e antigen (HBeAg) seropositive patients remain controversial. This study was conducted to address this issue.The long-term outcomes were compared in 233 IFN-treated patients and 233 well-matched untreated controls.METHODSThe long-term outcomes were compared in 233 IFN-treated patients and 233 well-matched untreated controls.The cumulative incidence at the end of 15 years of follow-up (median 6.8 years, range 1.1-16.5 years) in the IFN-treated patients and controls was: HBeAg seroconversion 74.6% vs. 51.7% (P=0.031); hepatitis B surface antigen (HBsAg) seroclearance 3% vs. 0.4% (P=0.03); cirrhosis 17.8% vs. 33.7% (P=0.041); and hepatocellular carcinoma (HCC) 2.7% vs. 12.5% (P=0.011). Significant reduction of HCC was only observed in patients with pre-existing cirrhosis (P<0.01). Compared with untreated controls with persistent HBeAg, HBeAg seroconverters in untreated and IFN-treated group showed significantly lower incidence of cirrhosis and HCC (P=0.003-0.031), while non-seroconverters of IFN-treated group had marginally significant lower incidence of cirrhosis (P=0.065). Multivariate analysis showed that IFN therapy, HBeAg seroconversion and genotype B HBV infection are independent factors for better long-term outcomes.RESULTSThe cumulative incidence at the end of 15 years of follow-up (median 6.8 years, range 1.1-16.5 years) in the IFN-treated patients and controls was: HBeAg seroconversion 74.6% vs. 51.7% (P=0.031); hepatitis B surface antigen (HBsAg) seroclearance 3% vs. 0.4% (P=0.03); cirrhosis 17.8% vs. 33.7% (P=0.041); and hepatocellular carcinoma (HCC) 2.7% vs. 12.5% (P=0.011). Significant reduction of HCC was only observed in patients with pre-existing cirrhosis (P<0.01). Compared with untreated controls with persistent HBeAg, HBeAg seroconverters in untreated and IFN-treated group showed significantly lower incidence of cirrhosis and HCC (P=0.003-0.031), while non-seroconverters of IFN-treated group had marginally significant lower incidence of cirrhosis (P=0.065). Multivariate analysis showed that IFN therapy, HBeAg seroconversion and genotype B HBV infection are independent factors for better long-term outcomes.IFN therapy reduces cirrhosis and HCC development.CONCLUSIONSIFN therapy reduces cirrhosis and HCC development. Background/Aims The long-term outcomes of interferon-alpha (IFN-α) therapy in hepatitis B e antigen (HBeAg) seropositive patients remain controversial. This study was conducted to address this issue. Methods The long-term outcomes were compared in 233 IFN-treated patients and 233 well-matched untreated controls. Results The cumulative incidence at the end of 15 years of follow-up (median 6.8 years, range 1.1–16.5 years) in the IFN-treated patients and controls was: HBeAg seroconversion 74.6% vs. 51.7% ( P = 0.031); hepatitis B surface antigen (HBsAg) seroclearance 3% vs. 0.4% ( P = 0.03); cirrhosis 17.8% vs. 33.7% ( P = 0.041); and hepatocellular carcinoma (HCC) 2.7% vs. 12.5% ( P = 0.011). Significant reduction of HCC was only observed in patients with pre-existing cirrhosis ( P < 0.01). Compared with untreated controls with persistent HBeAg, HBeAg seroconverters in untreated and IFN-treated group showed significantly lower incidence of cirrhosis and HCC ( P = 0.003–0.031), while non-seroconverters of IFN-treated group had marginally significant lower incidence of cirrhosis ( P = 0.065). Multivariate analysis showed that IFN therapy, HBeAg seroconversion and genotype B HBV infection are independent factors for better long-term outcomes. Conclusions IFN therapy reduces cirrhosis and HCC development. |
| Author | Yu, Ming-Lung Chien, Rong-Nan Lin, Shi-Ming Lee, Chuan-Mo Liaw, Yun-Fan Chu, Chia-Ming Sheen, I-Shyan |
| Author_xml | – sequence: 1 givenname: Shi-Ming surname: Lin fullname: Lin, Shi-Ming organization: Liver Research Unit, Chang Gung University and Chang Gung Memorial Hospital, Taipei, Taiwan – sequence: 2 givenname: Ming-Lung surname: Yu fullname: Yu, Ming-Lung organization: Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University and Hospital, Taiwan – sequence: 3 givenname: Chuan-Mo surname: Lee fullname: Lee, Chuan-Mo organization: Liver Unit, Chang Gung Memorial Hospital-Kaohsiung, Taiwan – sequence: 4 givenname: Rong-Nan surname: Chien fullname: Chien, Rong-Nan organization: Liver Research Unit, Chang Gung University and Chang Gung Memorial Hospital, Taipei, Taiwan – sequence: 5 givenname: I-Shyan surname: Sheen fullname: Sheen, I-Shyan organization: Liver Research Unit, Chang Gung University and Chang Gung Memorial Hospital, Taipei, Taiwan – sequence: 6 givenname: Chia-Ming surname: Chu fullname: Chu, Chia-Ming organization: Liver Research Unit, Chang Gung University and Chang Gung Memorial Hospital, Taipei, Taiwan – sequence: 7 givenname: Yun-Fan surname: Liaw fullname: Liaw, Yun-Fan email: liveryfl@so-net.net.tw organization: Liver Research Unit, Chang Gung University and Chang Gung Memorial Hospital, Taipei, Taiwan |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18418760$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17107734$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkt9rFDEQx4NU7LX6D_ggedG3XSfZX1mRQi1qCwUf1OeQnZ3t5dxLzmS3cP-9We5UKFifAsnnMxnmO2fsxHlHjL0UkAsQ9dtNvlnTLpcAdQ4qBymesJWoATKoS3HCVglSmZKNOmVnMW4AoIC2fMZORSOgaYpyxaYbN1EYKHjHpzUFs9tz6_j1B7q84zsf7WTvieM6vVvk6TszpavIA_UzUuS74O8CxWgX33O0IayTFblx_QH3SOM4jyZwNAGt81vznD0dzBjpxfE8Z98_ffx2dZ3dfvl8c3V5m2FV1VM2DJ0gEBWqVoEsGurKrhMtFlBWEqGWfQ99rypqlWzLoZJKQdNiVUhFyiAW5-zNoW7q8udMcdJbG5d2jCM_R12rolairBP46gjO3ZZ6vQt2a8Je_55TAl4fARPRjEMwDm38y6lSqKaGxKkDh8HHGGjQaKc0Mu-mYOyoBeglOr3RS3R6iU6D0im6pMoH6p_qj0nvDxKlMd5bCjqiJYfU20A46d7bx_WLBzqONgVtxh-0p7jxc3ApIC10lBr012Whln2CtGRV2S6De_fvAv_7_Rf6r9v_ |
| CODEN | JOHEEC |
| CitedBy_id | crossref_primary_10_1111_j_1365_2893_2010_01369_x crossref_primary_10_1016_j_jhep_2008_07_013 crossref_primary_10_1007_s12072_014_9551_7 crossref_primary_10_1007_s12072_013_9495_3 crossref_primary_10_1007_s12072_017_9807_0 crossref_primary_10_1016_j_clinre_2011_02_008 crossref_primary_10_1016_j_cgh_2009_05_025 crossref_primary_10_1111_j_1478_3231_2011_02490_x crossref_primary_10_15171_mejdd_2018_103 crossref_primary_10_1038_gt_2011_60 crossref_primary_10_1056_NEJMoa0802878 crossref_primary_10_1111_liv_14030 crossref_primary_10_1111_j_1478_3231_2012_02831_x crossref_primary_10_1186_s12876_020_01263_6 crossref_primary_10_1007_s12072_007_9006_5 crossref_primary_10_1016_j_jclinepi_2012_02_012 crossref_primary_10_1186_1471_2334_11_165 crossref_primary_10_1016_j_molimm_2016_03_011 crossref_primary_10_1111_j_1440_1746_2010_06271_x crossref_primary_10_3851_IMP1895 crossref_primary_10_1111_liv_12776 crossref_primary_10_1002_hep_28156 crossref_primary_10_2957_kanzo_54_402 crossref_primary_10_1007_s00262_010_0831_3 crossref_primary_10_1111_jgh_12436 crossref_primary_10_3138_canlivj_2018_0008 crossref_primary_10_1111_jvh_12059 crossref_primary_10_1155_2011_349575 crossref_primary_10_1093_carcin_bgr054 crossref_primary_10_1177_135965350801300314 crossref_primary_10_1002_hep_28280 crossref_primary_10_1007_s12072_014_9550_8 crossref_primary_10_1111_hepr_12269 crossref_primary_10_1002_hep_26300 crossref_primary_10_1016_j_jhep_2014_05_004 crossref_primary_10_1002_hep_26417 crossref_primary_10_1016_j_cld_2016_06_002 crossref_primary_10_5604_01_3001_0009_8590 crossref_primary_10_3748_wjg_v20_i37_13284 crossref_primary_10_1016_S1413_8670_10_70104_5 crossref_primary_10_1007_s11901_010_0036_4 crossref_primary_10_3892_mco_2014_386 crossref_primary_10_1016_j_virusres_2012_10_027 crossref_primary_10_1177_135965350801300201 crossref_primary_10_3390_jcm11041126 crossref_primary_10_1016_j_jhep_2010_02_035 crossref_primary_10_1007_s12072_008_9049_2 crossref_primary_10_1620_tjem_238_57 crossref_primary_10_1016_j_gcb_2009_06_006 crossref_primary_10_1007_s10620_010_1179_4 crossref_primary_10_1586_17474124_2016_1145547 crossref_primary_10_3390_biomedicines9111539 crossref_primary_10_2217_imt_2015_0021 crossref_primary_10_1586_eri_09_79 crossref_primary_10_1097_MD_0000000000010484 crossref_primary_10_1111_jvh_12755 crossref_primary_10_3389_fphar_2022_907921 crossref_primary_10_1159_000343857 crossref_primary_10_1016_j_cld_2011_03_001 crossref_primary_10_1111_j_1440_1746_2009_05985_x crossref_primary_10_1007_s12072_012_9365_4 crossref_primary_10_1016_j_micinf_2021_104802 crossref_primary_10_1111_j_1440_1746_2010_06285_x crossref_primary_10_1002_hep_22760 crossref_primary_10_1111_jvh_12928 crossref_primary_10_1148_radiol_2016151732 crossref_primary_10_3748_wjg_v20_i33_11595 crossref_primary_10_5812_hepatmon_34790 crossref_primary_10_1016_j_revmed_2019_03_333 crossref_primary_10_1016_j_cld_2010_05_006 crossref_primary_10_1016_j_jhep_2009_04_003 crossref_primary_10_1080_2331205X_2017_1340818 crossref_primary_10_1111_j_1365_2036_2010_04447_x crossref_primary_10_1016_j_jhep_2007_08_007 crossref_primary_10_1007_s12072_008_9080_3 crossref_primary_10_7314_APJCP_2013_14_9_4953 crossref_primary_10_1016_S1665_2681_19_31650_3 crossref_primary_10_1001_jama_2018_3795 crossref_primary_10_1016_j_bjid_2017_03_001 crossref_primary_10_1007_s11901_008_0020_4 crossref_primary_10_1111_j_1872_034X_2011_00801_x crossref_primary_10_1016_S0213_005X_08_76521_2 crossref_primary_10_3350_cmh_2016_22_1_18 crossref_primary_10_3851_IMP3240 crossref_primary_10_1055_a_1498_2512 crossref_primary_10_3851_IMP1982 crossref_primary_10_1016_j_ejphar_2018_06_030 crossref_primary_10_3851_IMP3366 crossref_primary_10_3851_IMP1621 crossref_primary_10_3390_ijerph13060604 crossref_primary_10_3851_IMP1622 crossref_primary_10_1136_bmjopen_2013_003265 crossref_primary_10_1016_S1499_3872_13_60041_7 crossref_primary_10_1038_mt_2008_160 crossref_primary_10_1016_j_jhep_2007_11_011 crossref_primary_10_1016_S1594_5804_09_60024_3 crossref_primary_10_1159_000368017 crossref_primary_10_1007_s00535_009_0024_z crossref_primary_10_3748_wjg_v21_i27_8249 crossref_primary_10_1111_hepr_12058 crossref_primary_10_1002_hep_26358 crossref_primary_10_1016_S1590_8658_10_60519_1 crossref_primary_10_1002_hep_25937 crossref_primary_10_1016_S0399_8320_10_70031_2 crossref_primary_10_1111_j_1478_3231_2008_01815_x crossref_primary_10_3390_jcm9123817 crossref_primary_10_1586_17474124_2_1_81 crossref_primary_10_18632_oncotarget_18075 crossref_primary_10_1007_s11901_011_0112_4 crossref_primary_10_1590_s1518_8787_2017051006693 crossref_primary_10_1586_17474124_2015_960398 crossref_primary_10_3389_fmicb_2021_665201 crossref_primary_10_2169_naika_101_2681 crossref_primary_10_3851_IMP1497 crossref_primary_10_1080_14712598_2018_1518423 crossref_primary_10_1007_s00535_014_1010_7 crossref_primary_10_3748_wjg_v28_i21_2251 crossref_primary_10_1053_j_seminoncol_2014_12_018 crossref_primary_10_1111_jvh_13667 crossref_primary_10_1097_MCG_0b013e3181faf0d1 crossref_primary_10_1111_j_1440_1746_2010_06576_x crossref_primary_10_1007_s11655_018_3011_5 crossref_primary_10_5124_jkma_2013_56_11_1001 crossref_primary_10_3748_wjg_14_6902 crossref_primary_10_1002_cam4_1998 crossref_primary_10_1016_j_jhep_2012_03_036 crossref_primary_10_1111_hepr_13194 crossref_primary_10_1111_j_1365_2036_2007_03297_x crossref_primary_10_1111_j_1478_3231_2009_02198_x crossref_primary_10_3350_kjhep_2009_15_2_179 crossref_primary_10_3748_wjg_v21_i46_13087 crossref_primary_10_1002_hep_30514 crossref_primary_10_1016_S1590_8658_10_60520_8 crossref_primary_10_1111_jvh_12468 crossref_primary_10_1053_j_gastro_2012_01_044 crossref_primary_10_1016_j_jhep_2009_11_010 crossref_primary_10_1016_j_jhepr_2024_101089 crossref_primary_10_1016_j_aidm_2014_07_001 crossref_primary_10_1016_j_cld_2013_05_005 crossref_primary_10_1007_s12072_014_9542_8 crossref_primary_10_1136_jclinpath_2011_200036 crossref_primary_10_1016_j_cyto_2018_08_012 crossref_primary_10_1055_s_0041_1729973 crossref_primary_10_1111_hepr_13504 crossref_primary_10_12998_wjcc_v7_i14_1784 crossref_primary_10_1371_journal_pone_0122259 crossref_primary_10_1007_s12072_020_10097_z crossref_primary_10_1016_S2468_1253_18_30308_X crossref_primary_10_1016_j_jhep_2006_10_008 crossref_primary_10_1111_j_1440_1746_2008_05400_x crossref_primary_10_14218_JCTH_2016_00019 crossref_primary_10_1517_14656566_2016_1118056 crossref_primary_10_1016_S0140_6736_09_60207_5 crossref_primary_10_1177_147323001003800122 crossref_primary_10_1111_j_1365_2036_2008_03816_x crossref_primary_10_1371_journal_pone_0107177 crossref_primary_10_2147_PGPM_S337962 crossref_primary_10_1097_MEG_0000000000000519 crossref_primary_10_1111_liv_13142 crossref_primary_10_1016_j_cgh_2019_04_044 crossref_primary_10_1111_j_1478_3231_2008_01941_x crossref_primary_10_3748_wjg_v26_i18_2166 crossref_primary_10_18632_oncotarget_10272 crossref_primary_10_1111_j_1478_3231_2010_02388_x crossref_primary_10_5812_hepatmon_8743 crossref_primary_10_1136_gutjnl_2013_305785 crossref_primary_10_1007_s00535_012_0548_5 crossref_primary_10_1016_j_biopha_2019_108846 crossref_primary_10_1016_j_jhep_2007_06_019 crossref_primary_10_1186_s12876_022_02541_1 crossref_primary_10_1007_s12072_008_9046_5 crossref_primary_10_1053_j_gastro_2018_09_052 crossref_primary_10_1158_1055_9965_EPI_07_2746 crossref_primary_10_1007_s12072_010_9165_7 crossref_primary_10_1155_2016_8682494 crossref_primary_10_1556_oh_2010_28881 crossref_primary_10_3350_cmh_2012_18_2_109 crossref_primary_10_1111_liv_12057 crossref_primary_10_1038_srep34088 crossref_primary_10_1111_jgh_12874 crossref_primary_10_1080_17474124_2019_1686975 crossref_primary_10_1007_s11812_009_0051_y crossref_primary_10_1016_j_jcv_2008_05_008 crossref_primary_10_1007_s11901_009_0022_x crossref_primary_10_1016_j_ramb_2013_03_005 crossref_primary_10_1016_j_jhep_2015_06_026 crossref_primary_10_1111_j_1872_034X_2011_00889_x crossref_primary_10_1053_j_gastro_2009_08_061 crossref_primary_10_1200_JCO_2007_14_4337 crossref_primary_10_4254_wjh_v7_i8_1097 crossref_primary_10_1007_s12072_016_9720_y crossref_primary_10_1002_hep_21723 crossref_primary_10_1038_s41598_021_87679_w crossref_primary_10_2165_11319850_000000000_00000 crossref_primary_10_14218_JCTH_2021_00209 crossref_primary_10_1111_liv_12394 crossref_primary_10_1002_hep_23348 crossref_primary_10_1007_s11655_020_3250_0 crossref_primary_10_1016_j_cca_2017_06_019 crossref_primary_10_1016_j_antiviral_2009_10_023 crossref_primary_10_1007_s12072_009_9140_3 crossref_primary_10_1111_j_1440_1746_2010_06545_x crossref_primary_10_1007_s11901_011_0109_z crossref_primary_10_1016_S1590_8658_10_60686_X crossref_primary_10_1517_14740338_2010_507190 crossref_primary_10_1586_14787210_2015_1093934 crossref_primary_10_1111_apt_13774 crossref_primary_10_1111_liv_12710 crossref_primary_10_1007_s12072_009_9149_7 crossref_primary_10_1111_liv_12395 crossref_primary_10_5501_wjv_v1_i6_174 crossref_primary_10_1016_j_cgh_2007_05_004 crossref_primary_10_18663_tjcl_590478 crossref_primary_10_1093_infdis_jiv547 crossref_primary_10_1111_liv_13372 crossref_primary_10_1517_13543784_17_10_1581 crossref_primary_10_1016_S1473_3099_07_70264_5 crossref_primary_10_1097_MEG_0000000000002598 crossref_primary_10_1111_j_1365_2893_2009_01070_x crossref_primary_10_1001_jama_2020_19750 crossref_primary_10_1007_s12072_007_5001_0 crossref_primary_10_1007_s00508_009_1298_0 crossref_primary_10_1016_j_cld_2007_08_009 crossref_primary_10_1002_jmv_29142 |
| Cites_doi | 10.1053/jhep.2003.50148 10.1053/jhep.2003.50458 10.1136/gut.2003.033324 10.1002/hep.1840200603 10.7326/0003-4819-142-10-200505170-00007 10.1111/j.2517-6161.1972.tb00899.x 10.7326/0003-4819-119-4-199308150-00011 10.1056/NEJMoa043470 10.1002/(SICI)1097-0142(19980301)82:5<827::AID-CNCR5>3.0.CO;2-G 10.1016/S0016-5085(00)70261-7 10.1016/S0168-8278(00)80135-X 10.1016/S0168-8278(03)00083-7 10.1053/jhep.2001.25273 10.1053/gast.1997.v113.pm9352870 10.1002/hep.510300113 10.7326/0003-4819-131-3-199908030-00003 10.1111/j.1365-2893.2004.00512.x 10.7326/0003-4819-142-2-200501180-00009 10.1056/NEJMoa013215 10.1002/hep.1840070102 10.1093/jnci/dji043 10.1002/hep.20128 10.1046/j.1365-2893.2003.00450.x 10.1111/j.1478-3231.2005.01134.x 10.1056/NEJM199605303342202 10.1016/S0168-8278(00)00094-5 10.1046/j.1440-1746.2002.02737.x 10.1002/hep.510300117 10.1002/hep.1840080310 10.1056/NEJMoa033364 10.1002/hep.510290312 10.1016/0016-5085(86)90919-4 10.7326/0003-4819-114-8-629 |
| ContentType | Journal Article |
| Copyright | 2006 European Association for the Study of the Liver European Association for the Study of the Liver 2007 INIST-CNRS |
| Copyright_xml | – notice: 2006 European Association for the Study of the Liver – notice: European Association for the Study of the Liver – notice: 2007 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.jhep.2006.08.021 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1600-0641 |
| EndPage | 52 |
| ExternalDocumentID | 17107734 18418760 10_1016_j_jhep_2006_08_021 S0168827806005496 1_s2_0_S0168827806005496 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29K 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 D-I DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDZ HMK HMO HVGLF HX~ HZ~ IHE J1W KOM LZ1 M27 M41 MJL MO0 N9A O-L O9- OAUVE OC. ON0 OVD OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K TEORI UV1 WUQ X7M YOC Z5R ZGI ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR AAYXX AGRNS CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c556t-ffb1e015c8980237eb4bb19c30452c062dd0dd85e98294f5288079c5328e8acc3 |
| IEDL.DBID | AIKHN |
| ISSN | 0168-8278 |
| IngestDate | Thu Sep 04 16:51:24 EDT 2025 Wed Feb 19 01:46:41 EST 2025 Mon Jul 21 09:16:23 EDT 2025 Thu Apr 24 22:52:51 EDT 2025 Tue Jul 01 04:13:55 EDT 2025 Fri Feb 23 02:30:42 EST 2024 Sun Feb 23 10:19:10 EST 2025 Tue Aug 26 16:52:41 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Cirrhosis Hepatocellular carcinoma Interferon Chronic hepatitis B HBeAg seroconversion Prognosis Cytokine Hepatic disease Malignant tumor Infection Viral hepatitis B Viral hepatitis A Chronic Treatment Viral disease Gastroenterology Digestive diseases Evolution Viral hepatitis E |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c556t-ffb1e015c8980237eb4bb19c30452c062dd0dd85e98294f5288079c5328e8acc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 17107734 |
| PQID | 68368146 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_68368146 pubmed_primary_17107734 pascalfrancis_primary_18418760 crossref_citationtrail_10_1016_j_jhep_2006_08_021 crossref_primary_10_1016_j_jhep_2006_08_021 elsevier_sciencedirect_doi_10_1016_j_jhep_2006_08_021 elsevier_clinicalkeyesjournals_1_s2_0_S0168827806005496 elsevier_clinicalkey_doi_10_1016_j_jhep_2006_08_021 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2007-01-01 |
| PublicationDateYYYYMMDD | 2007-01-01 |
| PublicationDate_xml | – month: 01 year: 2007 text: 2007-01-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford – name: Netherlands |
| PublicationTitle | Journal of hepatology |
| PublicationTitleAlternate | J Hepatol |
| PublicationYear | 2007 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Cox (bib18) 1972; 34 Yu, Yeh, Chen, Liaw, Lin, Liu (bib33) 2005; 97 EASL Jury. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol. 2003;38:533–540. Kanwal, Gralnek, Martin, Dulai, Farid, Spiegel (bib36) 2005; 142 Lin, Tai, Chien, Sheen, Chu, Liaw (bib9) 2004; 11 Korenman, Baker, Waggoner, Everhart, Di Bisceglie, Hoofnagle (bib8) 1991; 114 Kao, Wu, Chen, Lai, Chen (bib29) 2000; 33 Liaw, Sung, Chow, Farrell, Lee, Yuen (bib34) 2004; 351 Kao, Chen, Lai, Chen (bib31) 2000; 118 Lau, Everhart, Kleiner, Park, Vergalla, Schmid (bib7) 1997; 113 Wai, Chu, Hussain, Lok (bib30) 2002; 36 Lampertico, Del Ninno, Vigano, Romeo, Donato, Sablon (bib27) 2003; 37 Lau, Piratvisuth, Luo, Marcellin, Thongsawat, Coosley (bib23) 2005; 352 Papatheodoridis, Manesis, Hadziyannis (bib26) 2001; 34 Wong, Cheung, O’Rourke, Naylor, Detsky, Heathcote (bib2) 1993; 119 Cooksley, Piratvisuth, Lee, Mahachai, Chao, Tanwandee (bib22) 2003; 10 Liaw, Tai, Chu, Chen (bib17) 1988; 8 Liaw (bib14) 1995; 94 Janssen, Gerken, Carreno, Marcellin, Naoumov, Craxi (bib20) 1999; 30 Niederau, Heintges, Lange, Goldmann, Niederau, Mohr, Haussinger (bib4) 1996; 334 Lin, Sheen, Chien, Chu, Liaw (bib6) 1999; 29 Yuen, Hui, Cheng, Wu, Lai, Lai (bib10) 2001; 34 Liaw, Leung, Guan, Lau, Merican, McCaughan, Gane (bib19) 2005; 25 Cohard, Poynard, Mathurin, Zarski (bib3) 1994; 20 Chan, Hui, Wong, Tse, Hung, Wong (bib32) 2004; 53 van Zonneveld, Honkoop, Hansen, Niesters, Murad, de Man (bib11) 2004; 39 Chu, Liaw (bib1) 2004; 3 Liaw, Tai, Chu, Lin, Sheen, Chen, Pao (bib13) 1986; 90 Liaw, Pao, Chu, Sheen, Huang (bib15) 1987; 7 Carreno, Marcellin, Hadziyannis, Salmeron, Diago, Kitis (bib21) 1999; 30 Chien, Yeh, Tsai, Chu, Liaw (bib16) 2003; 38 Ikeda, Saitoh, Suzuki, Kobayashi, Tsubota, Fukuda, Koida (bib5) 1998; 82 Kao (bib12) 2002; 17 Yang, Lu, Liaw, You, Sun, Wang (bib28) 2002; 347 Yoshida, Shiratori, Moriyama, Arakawa, Ide, Sata (bib24) 1999; 131 Shiratori, Ito, Yokosuka, Imazeki, Nakata, Tanaka (bib25) 2005; 142 Cohard (10.1016/j.jhep.2006.08.021_bib3) 1994; 20 Yu (10.1016/j.jhep.2006.08.021_bib33) 2005; 97 Kao (10.1016/j.jhep.2006.08.021_bib29) 2000; 33 10.1016/j.jhep.2006.08.021_bib35 Liaw (10.1016/j.jhep.2006.08.021_bib34) 2004; 351 Kanwal (10.1016/j.jhep.2006.08.021_bib36) 2005; 142 Liaw (10.1016/j.jhep.2006.08.021_bib15) 1987; 7 Liaw (10.1016/j.jhep.2006.08.021_bib19) 2005; 25 Shiratori (10.1016/j.jhep.2006.08.021_bib25) 2005; 142 Yuen (10.1016/j.jhep.2006.08.021_bib10) 2001; 34 Liaw (10.1016/j.jhep.2006.08.021_bib13) 1986; 90 Yoshida (10.1016/j.jhep.2006.08.021_bib24) 1999; 131 Carreno (10.1016/j.jhep.2006.08.021_bib21) 1999; 30 Kao (10.1016/j.jhep.2006.08.021_bib31) 2000; 118 Kao (10.1016/j.jhep.2006.08.021_bib12) 2002; 17 Korenman (10.1016/j.jhep.2006.08.021_bib8) 1991; 114 Chien (10.1016/j.jhep.2006.08.021_bib16) 2003; 38 Yang (10.1016/j.jhep.2006.08.021_bib28) 2002; 347 Lin (10.1016/j.jhep.2006.08.021_bib6) 1999; 29 Janssen (10.1016/j.jhep.2006.08.021_bib20) 1999; 30 Lau (10.1016/j.jhep.2006.08.021_bib7) 1997; 113 Papatheodoridis (10.1016/j.jhep.2006.08.021_bib26) 2001; 34 Wai (10.1016/j.jhep.2006.08.021_bib30) 2002; 36 Chu (10.1016/j.jhep.2006.08.021_bib1) 2004; 3 Chan (10.1016/j.jhep.2006.08.021_bib32) 2004; 53 Lampertico (10.1016/j.jhep.2006.08.021_bib27) 2003; 37 van Zonneveld (10.1016/j.jhep.2006.08.021_bib11) 2004; 39 Lin (10.1016/j.jhep.2006.08.021_bib9) 2004; 11 Ikeda (10.1016/j.jhep.2006.08.021_bib5) 1998; 82 Wong (10.1016/j.jhep.2006.08.021_bib2) 1993; 119 Liaw (10.1016/j.jhep.2006.08.021_bib17) 1988; 8 Niederau (10.1016/j.jhep.2006.08.021_bib4) 1996; 334 Cox (10.1016/j.jhep.2006.08.021_bib18) 1972; 34 Cooksley (10.1016/j.jhep.2006.08.021_bib22) 2003; 10 Lau (10.1016/j.jhep.2006.08.021_bib23) 2005; 352 Liaw (10.1016/j.jhep.2006.08.021_bib14) 1995; 94 17112628 - J Hepatol. 2007 Jan;46(1):6-8 |
| References_xml | – volume: 34 start-page: 139 year: 2001 end-page: 145 ident: bib10 article-title: Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications publication-title: Hepatology – volume: 30 start-page: 238 year: 1999 end-page: 243 ident: bib20 article-title: Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment publication-title: Hepatology – volume: 131 start-page: 174 year: 1999 end-page: 181 ident: bib24 article-title: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. HIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy publication-title: Ann Intern Med – volume: 20 start-page: 1390 year: 1994 end-page: 1398 ident: bib3 article-title: Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect meta-analysis publication-title: Hepatology – volume: 17 start-page: 643 year: 2002 end-page: 650 ident: bib12 article-title: Hepatitis B viral genotypes: clinical relevance and molecular characteristics publication-title: J Gastroenterol Hepatol – volume: 34 start-page: 187 year: 1972 end-page: 220 ident: bib18 article-title: Regression model and life tables publication-title: J R Stat Soc B – volume: 25 start-page: 472 year: 2005 end-page: 489 ident: bib19 article-title: Asian Pacific consensus statement on the management of chronic hepatitis B: a 2005 update publication-title: Liver Int – volume: 94 start-page: 521 year: 1995 end-page: 528 ident: bib14 article-title: Acute exacerbation and superinfection in patients with chronic viral hepatitis publication-title: J Formosan Med Assoc – volume: 142 start-page: 105 year: 2005 end-page: 114 ident: bib25 article-title: Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival publication-title: Ann Intern Med – volume: 36 start-page: 1425 year: 2002 end-page: 1430 ident: bib30 article-title: HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C publication-title: Hepatology – volume: 37 start-page: 756 year: 2003 end-page: 763 ident: bib27 article-title: Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy publication-title: Hepatology – volume: 113 start-page: 1660 year: 1997 end-page: 1667 ident: bib7 article-title: Long-term follow up of patients with chronic hepatitis B treated with interferon alfa publication-title: Gastroenterology – volume: 119 start-page: 312 year: 1993 end-page: 323 ident: bib2 article-title: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. publication-title: Ann Intern Med – volume: 29 start-page: 971 year: 1999 end-page: 975 ident: bib6 article-title: Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection publication-title: Hepatology – volume: 39 start-page: 804 year: 2004 end-page: 810 ident: bib11 article-title: Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B publication-title: Hepatology – volume: 11 start-page: 349 year: 2004 end-page: 357 ident: bib9 article-title: Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B publication-title: J Viral Hepat – volume: 352 start-page: 2682 year: 2005 end-page: 2695 ident: bib23 article-title: Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B publication-title: New Engl J Med – reference: EASL Jury. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol. 2003;38:533–540. – volume: 97 start-page: 265 year: 2005 end-page: 272 ident: bib33 article-title: Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men publication-title: J Natl Cancer Inst – volume: 90 start-page: 263 year: 1986 end-page: 267 ident: bib13 article-title: Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study publication-title: Gastroenterology – volume: 351 start-page: 1521 year: 2004 end-page: 1531 ident: bib34 article-title: Lamivudine for patients with chronic hepatitis B and advanced liver disease publication-title: N Engl J Med – volume: 30 start-page: 277 year: 1999 end-page: 282 ident: bib21 article-title: Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP) publication-title: Hepatology – volume: 34 start-page: 306 year: 2001 end-page: 313 ident: bib26 article-title: The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B publication-title: J Hepatol – volume: 118 start-page: 554 year: 2000 end-page: 559 ident: bib31 article-title: Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B publication-title: Gastroenterology – volume: 3 start-page: 123 year: 2004 end-page: 131 ident: bib1 article-title: Natural history differences in perinatally versus adult-acquired disease publication-title: Curr Hepat Rep – volume: 10 start-page: 298 year: 2003 end-page: 305 ident: bib22 article-title: Peginterferon α-2a (40KD): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B publication-title: J Viral Hepat – volume: 53 start-page: 1494 year: 2004 end-page: 1498 ident: bib32 article-title: Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma publication-title: Gut – volume: 8 start-page: 493 year: 1988 end-page: 496 ident: bib17 article-title: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study publication-title: Hepatology – volume: 114 start-page: 629 year: 1991 end-page: 634 ident: bib8 article-title: Long-term remission of chronic hepatitis B after alpha-interferon therapy publication-title: Ann Intern Med – volume: 38 start-page: 1267 year: 2003 end-page: 1273 ident: bib16 article-title: Determinants for sustained HBeAg response to lamivudine therapy publication-title: Hepatology – volume: 347 start-page: 168 year: 2002 end-page: 174 ident: bib28 article-title: Hepatitis B e antigen and the risk of hepatocellular carcinoma publication-title: N Eng J Med – volume: 82 start-page: 827 year: 1998 end-page: 835 ident: bib5 article-title: Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus. A pilot study publication-title: Cancer – volume: 334 start-page: 1422 year: 1996 end-page: 1427 ident: bib4 article-title: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B publication-title: N Engl J Med – volume: 7 start-page: 1 year: 1987 end-page: 3 ident: bib15 article-title: Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis publication-title: Hepatology – volume: 33 start-page: 998 year: 2000 end-page: 1002 ident: bib29 article-title: Hepatitis B genotypes and the response to interferon therapy publication-title: J Hepatol – volume: 142 start-page: 821 year: 2005 end-page: 831 ident: bib36 article-title: Treatment alternatives for chronic hepatitis B virus infection: a cost-effective analysis publication-title: Ann Intern Med – volume: 37 start-page: 756 year: 2003 ident: 10.1016/j.jhep.2006.08.021_bib27 article-title: Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy publication-title: Hepatology doi: 10.1053/jhep.2003.50148 – volume: 3 start-page: 123 year: 2004 ident: 10.1016/j.jhep.2006.08.021_bib1 article-title: Natural history differences in perinatally versus adult-acquired disease publication-title: Curr Hepat Rep – volume: 38 start-page: 1267 year: 2003 ident: 10.1016/j.jhep.2006.08.021_bib16 article-title: Determinants for sustained HBeAg response to lamivudine therapy publication-title: Hepatology doi: 10.1053/jhep.2003.50458 – volume: 53 start-page: 1494 year: 2004 ident: 10.1016/j.jhep.2006.08.021_bib32 article-title: Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma publication-title: Gut doi: 10.1136/gut.2003.033324 – volume: 20 start-page: 1390 year: 1994 ident: 10.1016/j.jhep.2006.08.021_bib3 article-title: Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect meta-analysis publication-title: Hepatology doi: 10.1002/hep.1840200603 – volume: 142 start-page: 821 year: 2005 ident: 10.1016/j.jhep.2006.08.021_bib36 article-title: Treatment alternatives for chronic hepatitis B virus infection: a cost-effective analysis publication-title: Ann Intern Med doi: 10.7326/0003-4819-142-10-200505170-00007 – volume: 34 start-page: 187 year: 1972 ident: 10.1016/j.jhep.2006.08.021_bib18 article-title: Regression model and life tables publication-title: J R Stat Soc B doi: 10.1111/j.2517-6161.1972.tb00899.x – volume: 119 start-page: 312 year: 1993 ident: 10.1016/j.jhep.2006.08.021_bib2 article-title: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. publication-title: Ann Intern Med doi: 10.7326/0003-4819-119-4-199308150-00011 – volume: 352 start-page: 2682 year: 2005 ident: 10.1016/j.jhep.2006.08.021_bib23 article-title: Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B publication-title: New Engl J Med doi: 10.1056/NEJMoa043470 – volume: 82 start-page: 827 year: 1998 ident: 10.1016/j.jhep.2006.08.021_bib5 article-title: Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus. A pilot study publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19980301)82:5<827::AID-CNCR5>3.0.CO;2-G – volume: 118 start-page: 554 year: 2000 ident: 10.1016/j.jhep.2006.08.021_bib31 article-title: Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B publication-title: Gastroenterology doi: 10.1016/S0016-5085(00)70261-7 – volume: 33 start-page: 998 year: 2000 ident: 10.1016/j.jhep.2006.08.021_bib29 article-title: Hepatitis B genotypes and the response to interferon therapy publication-title: J Hepatol doi: 10.1016/S0168-8278(00)80135-X – ident: 10.1016/j.jhep.2006.08.021_bib35 doi: 10.1016/S0168-8278(03)00083-7 – volume: 34 start-page: 139 year: 2001 ident: 10.1016/j.jhep.2006.08.021_bib10 article-title: Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications publication-title: Hepatology doi: 10.1053/jhep.2001.25273 – volume: 113 start-page: 1660 year: 1997 ident: 10.1016/j.jhep.2006.08.021_bib7 article-title: Long-term follow up of patients with chronic hepatitis B treated with interferon alfa publication-title: Gastroenterology doi: 10.1053/gast.1997.v113.pm9352870 – volume: 30 start-page: 238 year: 1999 ident: 10.1016/j.jhep.2006.08.021_bib20 article-title: Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment publication-title: Hepatology doi: 10.1002/hep.510300113 – volume: 131 start-page: 174 year: 1999 ident: 10.1016/j.jhep.2006.08.021_bib24 article-title: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. HIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy publication-title: Ann Intern Med doi: 10.7326/0003-4819-131-3-199908030-00003 – volume: 11 start-page: 349 year: 2004 ident: 10.1016/j.jhep.2006.08.021_bib9 article-title: Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2004.00512.x – volume: 142 start-page: 105 year: 2005 ident: 10.1016/j.jhep.2006.08.021_bib25 article-title: Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival publication-title: Ann Intern Med doi: 10.7326/0003-4819-142-2-200501180-00009 – volume: 347 start-page: 168 year: 2002 ident: 10.1016/j.jhep.2006.08.021_bib28 article-title: Hepatitis B e antigen and the risk of hepatocellular carcinoma publication-title: N Eng J Med doi: 10.1056/NEJMoa013215 – volume: 7 start-page: 1 year: 1987 ident: 10.1016/j.jhep.2006.08.021_bib15 article-title: Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis publication-title: Hepatology doi: 10.1002/hep.1840070102 – volume: 94 start-page: 521 year: 1995 ident: 10.1016/j.jhep.2006.08.021_bib14 article-title: Acute exacerbation and superinfection in patients with chronic viral hepatitis publication-title: J Formosan Med Assoc – volume: 97 start-page: 265 year: 2005 ident: 10.1016/j.jhep.2006.08.021_bib33 article-title: Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji043 – volume: 39 start-page: 804 year: 2004 ident: 10.1016/j.jhep.2006.08.021_bib11 article-title: Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B publication-title: Hepatology doi: 10.1002/hep.20128 – volume: 10 start-page: 298 year: 2003 ident: 10.1016/j.jhep.2006.08.021_bib22 article-title: Peginterferon α-2a (40KD): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B publication-title: J Viral Hepat doi: 10.1046/j.1365-2893.2003.00450.x – volume: 25 start-page: 472 year: 2005 ident: 10.1016/j.jhep.2006.08.021_bib19 article-title: Asian Pacific consensus statement on the management of chronic hepatitis B: a 2005 update publication-title: Liver Int doi: 10.1111/j.1478-3231.2005.01134.x – volume: 334 start-page: 1422 year: 1996 ident: 10.1016/j.jhep.2006.08.021_bib4 article-title: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B publication-title: N Engl J Med doi: 10.1056/NEJM199605303342202 – volume: 34 start-page: 306 year: 2001 ident: 10.1016/j.jhep.2006.08.021_bib26 article-title: The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B publication-title: J Hepatol doi: 10.1016/S0168-8278(00)00094-5 – volume: 17 start-page: 643 year: 2002 ident: 10.1016/j.jhep.2006.08.021_bib12 article-title: Hepatitis B viral genotypes: clinical relevance and molecular characteristics publication-title: J Gastroenterol Hepatol doi: 10.1046/j.1440-1746.2002.02737.x – volume: 36 start-page: 1425 year: 2002 ident: 10.1016/j.jhep.2006.08.021_bib30 article-title: HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C publication-title: Hepatology – volume: 30 start-page: 277 year: 1999 ident: 10.1016/j.jhep.2006.08.021_bib21 article-title: Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP) publication-title: Hepatology doi: 10.1002/hep.510300117 – volume: 8 start-page: 493 year: 1988 ident: 10.1016/j.jhep.2006.08.021_bib17 article-title: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study publication-title: Hepatology doi: 10.1002/hep.1840080310 – volume: 351 start-page: 1521 year: 2004 ident: 10.1016/j.jhep.2006.08.021_bib34 article-title: Lamivudine for patients with chronic hepatitis B and advanced liver disease publication-title: N Engl J Med doi: 10.1056/NEJMoa033364 – volume: 29 start-page: 971 year: 1999 ident: 10.1016/j.jhep.2006.08.021_bib6 article-title: Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection publication-title: Hepatology doi: 10.1002/hep.510290312 – volume: 90 start-page: 263 year: 1986 ident: 10.1016/j.jhep.2006.08.021_bib13 article-title: Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study publication-title: Gastroenterology doi: 10.1016/0016-5085(86)90919-4 – volume: 114 start-page: 629 year: 1991 ident: 10.1016/j.jhep.2006.08.021_bib8 article-title: Long-term remission of chronic hepatitis B after alpha-interferon therapy publication-title: Ann Intern Med doi: 10.7326/0003-4819-114-8-629 – reference: 17112628 - J Hepatol. 2007 Jan;46(1):6-8 |
| SSID | ssj0003094 |
| Score | 2.3689537 |
| Snippet | The long-term outcomes of interferon-alpha (IFN-α) therapy in hepatitis B e antigen (HBeAg) seropositive patients remain controversial. This study was... Background/Aims The long-term outcomes of interferon-alpha (IFN-α) therapy in hepatitis B e antigen (HBeAg) seropositive patients remain controversial. This... The long-term outcomes of interferon-alpha (IFN-alpha) therapy in hepatitis B e antigen (HBeAg) seropositive patients remain controversial. This study was... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 45 |
| SubjectTerms | Adult Antiviral Agents - therapeutic use Biological and medical sciences Carcinoma, Hepatocellular - prevention & control Case-Control Studies Chronic hepatitis B Cirrhosis Female Follow-Up Studies Gastroenterology and Hepatology Gastroenterology. Liver. Pancreas. Abdomen Genotype HBeAg seroconversion Hepacivirus - genetics Hepatitis B e Antigens - blood Hepatitis B, Chronic - complications Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - etiology Hepatocellular carcinoma Human viral diseases Humans Infectious diseases Interferon Interferon Type I - therapeutic use Liver Cirrhosis - prevention & control Liver Neoplasms - prevention & control Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Other diseases. Semiology Recombinant Proteins Tumors Viral diseases Viral hepatitis |
| Title | Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0168827806005496 https://www.clinicalkey.es/playcontent/1-s2.0-S0168827806005496 https://dx.doi.org/10.1016/j.jhep.2006.08.021 https://www.ncbi.nlm.nih.gov/pubmed/17107734 https://www.proquest.com/docview/68368146 |
| Volume | 46 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB61WwkhIcSb8Fh84IbSTZzYcY7Limp5tEJApd6srOPQVJCskhSJC7-dmbWzVQUtEtfIkzie16fxPABeZlLaMuElWj9lw1QJG-Z5WYTCiswWUlSmogLnwyO5PE7fnYiTHViMtTCUVultv7PpG2vtn8z8ac7WdT37jGAF4WGmIkm4I5e7sMfR26sJ7M3fvl8ebQ1yEuW-xbcKicDXzrg0r7NTu_Z3Emo_4vFV_unWuujx1Co37uJqPLrxSwd34LYHlGzu9nwXdmxzD24c-ivz-zBsYn6V7dqGuWKrn6xu2PK1nX9lLmXrh2XG9chluE2Sn7pnHfV0tT3bJHC55h1saJmpu-4UqXpWNKVb3lLwn7JZmaHBRE37vXgAxwdvviyWoR-1EBoh5BBW1Sq2iAyMyqkjXGZX6WoV54buUbmJJC_LqCyRk7nieVoJjmqf5UYkXFlVGJM8hEnTNvYxsFSZiB4ilpOppe46CIk5vi6JTSrKPIB4PGBtfB9yGofxTY8JZ2eamEIDMqWmGZk8DuDVlmbtunBcuzoZ-abH-lK0iBqdxLVU2d-obO-Vutex7rmO9B-CF4DYUl6S3X9-cXpJqC5-TaUxeqkogBejlGnUeuJm0dj2vNdSJZKCtwE8csJ3QYuQMcuS9Ml_buop3HTha4oyPYPJ0J3b54i7htUUdvd_xVPUrsWnDx-nXst-A63kLmw |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JT90wELYolVqkqupK0wV86K0KL4vt2EeKil5bHpeCxM1KHKcEQfKUhEq98NuZiR2eUAuVeo08iTObP41nIeRjJoQt06QE7ydtyCS3oVJlHnLLM5sLXpkKC5wXh2J-zL6d8JM1sjfVwmBapff9zqeP3to_mXluzpZ1PfsBYAXgYSYjgbhDiQfkIcMxB6DUO1erPI80Ur7Btwxxua-ccUleZ6d26W8k5E6UxHedTk-WeQ88q9ywi7vR6Hgq7T8jTz2cpLtux8_Jmm1ekEcLf2H-kgxjxK-yXdtQV2r1m9YNnX-2uz-pS9j6ZalxHXIpbBO1p-5phx1dbU_H9C3XuoMOLTV1150CVU_zpnTLWwz9Yy4rNTiWqGkv8lfkeP_L0d489IMWQsO5GMKqKmILuMBIhf3gMluwooiVwVvUxEQiKcuoLEGOSiaKVTwBo8-UAWZLK3Nj0tdkvWkb-4ZQJk2EDwHJCWaxtw4A4gRel8aG8VIFJJ4YrI3vQo7DMM71lG52plEoOB5TaJyQmcQB-XRDs3Q9OO5dnU5y01N1KfhDDUfEvVTZ36hs702617HuEx3pP9QuIPyG8pbm_vOLW7eUavVrksVwRkUB2Z60TIPNozTzxraXvRYyFRi6DcimU74VLQDGLEvZ2__c1DZ5PD9aHOiDr4ff35ENF8jGeNN7sj50l_YDILCh2Bot7Bq1My2Z |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Interferon+therapy+in+HBeAg+positive+chronic+hepatitis+reduces+progression+to+cirrhosis+and+hepatocellular+carcinoma&rft.jtitle=Journal+of+hepatology&rft.au=Lin%2C+Shi-Ming&rft.au=Yu%2C+Ming-Lung&rft.au=Lee%2C+Chuan-Mo&rft.au=Chien%2C+Rong-Nan&rft.date=2007-01-01&rft.issn=0168-8278&rft.volume=46&rft.issue=1&rft.spage=45&rft.epage=52&rft_id=info:doi/10.1016%2Fj.jhep.2006.08.021&rft.externalDBID=ECK1-s2.0-S0168827806005496&rft.externalDocID=1_s2_0_S0168827806005496 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01688278%2FS0168827806X01915%2Fcov150h.gif |